Sunday, July 24, 2011
Side Effects of New Anti-Platelet Drug, Ticagrelor (ContributorNetwork)
ContributorNetwork - The FDA on Wednesday approved the new anti-platelet drug, ticagrelor, for patients with acute coronary syndrome. The goal of therapy with this blood-thinning agent, also known as Brilinta, is to decrease the rates of heart attacks and cardiovascular deaths in these patients. Similar to the popular drug Plavix, ticagrelor has side effects common to anti-platelet medications, mostly related to bleeding. Here is a summary of the most commonly occurring side effects with anti-platelet therapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment